Resource Logo
NLM AIDSLINE

A triple nucleoside analogue combination in four patients with primary HIV-1 infections: towards complete virological remissions?




 

Int Conf AIDS. 1996 Jul 7-12;11(1):112 (abstract no. Mo.B.1332). Unique

Objectives: By introducing a convergent combination of Thymidine, Cytidine, Adenosine analogues altogether within 6 weeks in patients with primary retroviral infection, to obtain such a blockade of HIV activity in vivo as to stop treatment after 12 months of its initiation. Patients and methods: Three men, 1 woman (aged 35-38) received zidovudine (AZT) (250 mg tid), didanosine (ddI) (200 mg bid), and lamivudine (3TC) (150 mg bid) during the course of a clinically overt primary HIV-1 infection documented by both sequential Western Blots and plasma viremias. Log HIV infectious blood cells/107 PBMCs [lower limit of detection 0.7(a)], and Log HIV RNA copies/ml plasma (Amplicor Monitor Roche, 36 cycles, limit of detectionl(b)) were sequentially determined in real time. Results: (table: see text) Conclusion: In all 4 patients, virus became undetectable in either cells or plasma or both by weeks 12-16 of treatment. Patient G has been off antivirals for 3 months since week 52 without recurrence of retroviral activity in blood cells or plasma.

*Antiviral Agents/THERAPEUTIC USE *Didanosine/THERAPEUTIC USE *HIV Infections/DRUG THERAPY *HIV-1/ISOLATION & PURIF *Zidovudine/THERAPEUTIC USE



 




Information in this article was accurate in January 30, 1997. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.